Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2535)	4/16/2010 11:47:12 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

IMGN was up 10.44% and is still up 8.22% with volume now > 3x its ADV The stock is still trading above its Dec9 H of $9.55 bigcharts.marketwatch.com IMGN announced yesterday that Roche has provided a favorable update related to its plans to apply for marketing approval of T-DM1 in the US. T-DM1 is in global development by the Roche Group under a collaboration agreement between DNA and IMGN.<g> DNA/Roche plan to submit a marketing application to the FDA in 2010 to use of T-DM1 for treatment of advanced HER2-positive metastatic breast Ca. IMGN has reported significantly lower revenues in the first 2Qs and losses have been higher. The EL for 2010 is around $0.95 vs. $0.62 in 2009 The stock next resistance is the July2009 H at $10.13 and then the April 2004 H at $12.40 The Nov2000 H was $45.90 <g> bigcharts.marketwatch.com Bernard